Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aspire-Lakewood Holdings, Inc.PWUP · Entity 7885 | Director | August 18, 2023 | August 28, 2023 |
| Crown Reserve Acquisition Corp. ICRAC · Entity 6210 | Director | September 26, 2025 | October 23, 2025 |
| DataMeds AI, Inc.WGRX · Entity 8434 | Director | July 02, 2025 | July 08, 2025 |
| Indonesia Energy Corp LtdINDO · Entity 7227 | Director | March 18, 2026 | March 18, 2026 |
| Integrated Wellness Acquisition CorpWEL · Entity 85241 | Director | February 12, 2024 | February 21, 2024 |
| Ocean Biomedical, Inc.OCEA · Entity 8695 | Director | February 28, 2023 | March 02, 2023 |
| OceanTech Acquisitions I Corp.OTEC · Entity 112900 | Director | March 13, 2023 | April 21, 2023 |
| Scienture Holdings, Inc.MEDS · Entity 7802 | Director | January 16, 2023 | January 20, 2023 |
| Tevogen Inc.LGST · Entity 7276 | Director | June 07, 2023 | June 14, 2023 |
| Trio Petroleum CorpTPET · Entity 8017 | Director · Chief Executive Officer | October 23, 2023 | October 30, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aspire-Lakewood Holdings, Inc.
Report date August 18, 2023 · Filed August 28, 2023
This filing explicitly reported no securities owned.
Crown Reserve Acquisition Corp. I
Report date September 26, 2025 · Filed October 23, 2025
This filing explicitly reported no securities owned.
DataMeds AI, Inc.
Report date July 02, 2025 · Filed July 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
After 2025-07-02 transaction · row 1
1 source rowRow 1 · 2025-07-02 · Grant · Disposed 200,000 · Balance 200,000 F1: The shares shall fully vest solely on the basis of the passage of time, with 66,000 shares vesting immediately, 67,000 shares vesting on July 2, 2026, and 67,000 shares vesting on July 2, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares shall fully vest solely on the basis of the passage of time, with 66,000 shares vesting immediately, 67,000 shares vesting on July 2, 2026, and 67,000 shares vesting on July 2, 2027.
Indonesia Energy Corp Ltd
Report date March 18, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.79 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-03-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: Represents options granted on December 16, 2024 under the Issuer's 2018 Omnibus Equity Incentive Plan to purchase 20,000 ordinary shares of the Issuer at $2.79 per share, which were fully vested and exercisable on December 16, 2024, with expiry on December 16, 2034. On March 18, such options have not been exercised. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents options granted on December 16, 2024 under the Issuer's 2018 Omnibus Equity Incentive Plan to purchase 20,000 ordinary shares of the Issuer at $2.79 per share, which were fully vested and exercisable on December 16, 2024, with expiry on December 16, 2034. On March 18, such options have not been exercised.
Integrated Wellness Acquisition Corp
Report date February 12, 2024 · Filed February 21, 2024
This filing explicitly reported no securities owned.
Ocean Biomedical, Inc.
Report date February 28, 2023 · Filed March 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.0001SEC Table I · non-derivative | Direct | 80,000 |
Reported balance
After 2023-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-28 · Other · Acquired 80,000 · Balance 80,000 F1: In connection with the closing on February 14, 2023 (the "Closing") of the business combination (the "Business Combination") between Aesther Healthcare Acquisition Corp. ("AHAC") and Ocean Biomedical Holdings, Inc., formerly known as Ocean Biomedical, Inc. ("Legacy Ocean"), pursuant to that certain Agreement and Plan of Merger, dated August 31, 2022 and amended on December 5, 2022, between AHAC, Aesther Healthcare Sponsor, LLC (the "Sponsor"), AHAC Merger Sub, Inc. ("Merger Sub"), Legacy Ocean, and Dr. Chirinjeev Kathuria, AHAC changed its name to Ocean Biomedical, Inc. (such post-Business Combination entity, the "Issuer"). F2: Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation filed in connection with the Closing of the Business Combination, the Issuer completed a reclassification exempt under Rule 16b-7 (the "Reclassification"). In accordance with the Reclassification, each share of the Issuer's Class A Common Stock, par value $0.0001 per share (the "Class A Common Stock"), was reclassified on a one-for-one basis into a share of the Issuer's common stock, par value $0.0001 (the "Common Stock"). F3: These shares were originally among the 2,625,000 shares of AHAC's Class B Common Stock, par value $0.0001 per share (the "Class B Founder Shares"), that the Sponsor owned prior to the Business Combination. In connection with the Closing of the Business Combination, the Class B Founder Shares automatically converted into shares of the Issuer's Class A Common Stock on a one-for-one basis, and the Class A Common Stock was then reclassified on a one-for-one basis into Common Stock in accordance with the Reclassification. F4: In accordance with an instruction letter to the Sponsor's transfer agent (the "Instruction Letter"), the Sponsor instructed the transfer agent to transfer 2,625,000 shares of Common Stock to certain of the Sponsor's members for no consideration (such transaction, the "Transfer"). As part of the Transfer, the Reporting Person acquired 80,000 shares of Common Stock from the Sponsor. |
| Private Placement WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $11.50 · Expires 2028-02-14 | Direct | 200,000 |
Reported balance
After 2023-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-02-28 · Other · Acquired 200,000 · Balance 200,000 F5: Simultaneously with the closing of the AHAC's initial public offering on September 17, 2021, the Sponsor purchased 5,411,000 warrants (the "Private Placement Warrants") from AHAC in a private placement at a price of $1.00 per warrant, pursuant to the terms of the Private Placement Warrants Purchase Agreement between AHAC and the Sponsor dated September 14, 2021 (the "Private Placement Agreement"). Upon the Reclassification that was effected in connection with the Closing of the Business Combination, each share of Class A Common Stock underlying the Private Placement Warrants was reclassified into a share of the Issuer's Common Stock. F6: According to the original terms of the Private Placement Agreement, each Private Placement Warrant was exercisable to purchase one share of the Issuer's Class A Common Stock at an exercise price of $11.50 per share. The terms of the Private Placement Warrant were set forth in the Warrant Agreement, dated September 14, 2021, between AHAC and Continental Stock Transfer & Trust Company, LLC (the "Warrant Agreement"). The Private Placement Warrants become exercisable 30 days after the Closing of the Business Combination. F7: On February 28, 2023, in accordance with the Instruction Letter, the Sponsor instructed its transfer agent to distribute these Private Placement Warrants to the Reporting Person. F8: The Private Placement Warrants expire on the earlier to occur of (i) February 14, 2028, the date that is five years after the Closing of the Business Combination, (ii) at 5:00 p.m., New York City time on the Redemption Date (as defined in the Warrant Agreement), and (iii) the liquidation of the Trust Account (as defined in the Warrant Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the closing on February 14, 2023 (the "Closing") of the business combination (the "Business Combination") between Aesther Healthcare Acquisition Corp. ("AHAC") and Ocean Biomedical Holdings, Inc., formerly known as Ocean Biomedical, Inc. ("Legacy Ocean"), pursuant to that certain Agreement and Plan of Merger, dated August 31, 2022 and amended on December 5, 2022, between AHAC, Aesther Healthcare Sponsor, LLC (the "Sponsor"), AHAC Merger Sub, Inc. ("Merger Sub"), Legacy Ocean, and Dr. Chirinjeev Kathuria, AHAC changed its name to Ocean Biomedical, Inc. (such post-Business Combination entity, the "Issuer").
F2: Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation filed in connection with the Closing of the Business Combination, the Issuer completed a reclassification exempt under Rule 16b-7 (the "Reclassification"). In accordance with the Reclassification, each share of the Issuer's Class A Common Stock, par value $0.0001 per share (the "Class A Common Stock"), was reclassified on a one-for-one basis into a share of the Issuer's common stock, par value $0.0001 (the "Common Stock").
F3: These shares were originally among the 2,625,000 shares of AHAC's Class B Common Stock, par value $0.0001 per share (the "Class B Founder Shares"), that the Sponsor owned prior to the Business Combination. In connection with the Closing of the Business Combination, the Class B Founder Shares automatically converted into shares of the Issuer's Class A Common Stock on a one-for-one basis, and the Class A Common Stock was then reclassified on a one-for-one basis into Common Stock in accordance with the Reclassification.
F4: In accordance with an instruction letter to the Sponsor's transfer agent (the "Instruction Letter"), the Sponsor instructed the transfer agent to transfer 2,625,000 shares of Common Stock to certain of the Sponsor's members for no consideration (such transaction, the "Transfer"). As part of the Transfer, the Reporting Person acquired 80,000 shares of Common Stock from the Sponsor.
F5: Simultaneously with the closing of the AHAC's initial public offering on September 17, 2021, the Sponsor purchased 5,411,000 warrants (the "Private Placement Warrants") from AHAC in a private placement at a price of $1.00 per warrant, pursuant to the terms of the Private Placement Warrants Purchase Agreement between AHAC and the Sponsor dated September 14, 2021 (the "Private Placement Agreement"). Upon the Reclassification that was effected in connection with the Closing of the Business Combination, each share of Class A Common Stock underlying the Private Placement Warrants was reclassified into a share of the Issuer's Common Stock.
F6: According to the original terms of the Private Placement Agreement, each Private Placement Warrant was exercisable to purchase one share of the Issuer's Class A Common Stock at an exercise price of $11.50 per share. The terms of the Private Placement Warrant were set forth in the Warrant Agreement, dated September 14, 2021, between AHAC and Continental Stock Transfer & Trust Company, LLC (the "Warrant Agreement"). The Private Placement Warrants become exercisable 30 days after the Closing of the Business Combination.
F7: On February 28, 2023, in accordance with the Instruction Letter, the Sponsor instructed its transfer agent to distribute these Private Placement Warrants to the Reporting Person.
F8: The Private Placement Warrants expire on the earlier to occur of (i) February 14, 2028, the date that is five years after the Closing of the Business Combination, (ii) at 5:00 p.m., New York City time on the Redemption Date (as defined in the Warrant Agreement), and (iii) the liquidation of the Trust Account (as defined in the Warrant Agreement).
OceanTech Acquisitions I Corp.
Report date March 13, 2023 · Filed April 21, 2023
This filing explicitly reported no securities owned.
Scienture Holdings, Inc.
Report date January 16, 2023 · Filed January 20, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 118,940 |
Reported balance
After 2023-01-16 transaction · row 1
1 source rowRow 1 · 2023-01-16 · Grant · Acquired 100,000 · Balance 118,940 F1: Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/8th of such shares per quarter (on the first day of each calendar quarter), with the first vesting beginning on April 1, 2023, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3. F2: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer and Chairperson of the Audit Committee. Issued under the Issuer's Amended and Restated 2019 Equity Incentive Plan. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.41 · Expires 2033-01-16 | Direct | 135,802 |
Reported balance
After 2023-01-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-16 · Grant · Acquired 135,802 · Balance 135,802 F2: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer and Chairperson of the Audit Committee. Issued under the Issuer's Amended and Restated 2019 Equity Incentive Plan. F3: The options vest at the rate of 1/2 of such options per year, on January 4, 2024 and 2025, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/8th of such shares per quarter (on the first day of each calendar quarter), with the first vesting beginning on April 1, 2023, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3.
F2: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer and Chairperson of the Audit Committee. Issued under the Issuer's Amended and Restated 2019 Equity Incentive Plan.
F3: The options vest at the rate of 1/2 of such options per year, on January 4, 2024 and 2025, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3.
Tevogen Inc.
Report date June 07, 2023 · Filed June 14, 2023
This filing explicitly reported no securities owned.
Trio Petroleum Corp
Report date October 23, 2023 · Filed October 30, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,185,000 |
Reported balance
After 2023-10-23 transaction · row 1
1 source rowRow 1 · 2023-10-23 · Grant · Acquired 1,000,000 · Balance 1,185,000 F1: Mr. Peterson was awarded 1,000,000 shares of restricted stock (the "Stock Grant"), pursuant to the Issuer's 2022 Equity Incentive Plan (the "2022 Plan"), under the terms of an employment agreement entered into between the Issuer and Mr. Peterson, who became the Issuer's Chief Executive Officer, effective as of October 23, 2023. The Stock Grant has a vesting schedule in which the first 250,000 shares of restricted stock will vest on April 23, 2024, and the remainder shall vest in equal tranches of 250,000 shares each on October 23, 2024, April 23, 2025 and October 23, 2025, subject to Mr. Peterson's remaining in Continuous Service (as such term is defined under the 2022 Plan) with the Company as of each of those dates. F2: The shares of restricted stock were awarded as a bonus under Mr. Peterson's employment agreement in connection with his services as the Chief Executive Officer of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Mr. Peterson was awarded 1,000,000 shares of restricted stock (the "Stock Grant"), pursuant to the Issuer's 2022 Equity Incentive Plan (the "2022 Plan"), under the terms of an employment agreement entered into between the Issuer and Mr. Peterson, who became the Issuer's Chief Executive Officer, effective as of October 23, 2023. The Stock Grant has a vesting schedule in which the first 250,000 shares of restricted stock will vest on April 23, 2024, and the remainder shall vest in equal tranches of 250,000 shares each on October 23, 2024, April 23, 2025 and October 23, 2025, subject to Mr. Peterson's remaining in Continuous Service (as such term is defined under the 2022 Plan) with the Company as of each of those dates.
F2: The shares of restricted stock were awarded as a bonus under Mr. Peterson's employment agreement in connection with his services as the Chief Executive Officer of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
PEDEVCO CORP
Report date June 28, 2018 · Filed June 29, 2018
Section 16 reporting ended · disclosed 2018-06-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 442,081 |
Reported balance
After 2018-06-28 transaction · row 1
1 source rowRow 1 · 2018-06-28 · Sale · Disposed 119,000 · Balance 442,081 F1: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the June 28, 2018 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). |
| Common StockSEC Table I · non-derivative | IndirectBy The Peterson Family Trust | 521 |
Reported balance
Holding disclosure · report date 2018-06-28 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 521 F2: Represents shares held by The Peterson Family Trust, a trust owned 100% by Mr. Peterson and his spouse. |
| Common StockSEC Table I · non-derivative | IndirectBy dependent child | 1,834 |
Reported balance
Holding disclosure · report date 2018-06-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 1,834 F3: Represents shares held by Reporting Person's dependent child. |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.20 · Expires 2021-01-07 | Direct | 30,000 |
Reported balance
Holding disclosure · report date 2018-06-28 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 30,000 |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.70 · Expires 2020-01-07 | Direct | 32,500 |
Reported balance
Holding disclosure · report date 2018-06-28 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 32,500 |
| Incentive Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2022-06-18 | Direct | 6,380 |
Reported balance
Holding disclosure · report date 2018-06-28 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 6,380 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.40 · Expires 2022-06-18 | Direct | 10,000 |
Reported balance
Holding disclosure · report date 2018-06-28 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 10,000 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.10 · Expires 2022-06-18 | Direct | 26,954 |
Reported balance
Holding disclosure · report date 2018-06-28 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 26,954 |
| Non-Qualified Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $302.40 · Expires 2021-02-02 | Direct | 298 |
Reported balance
Holding disclosure · report date 2018-06-28 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 298 |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the June 28, 2018 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d).
F2: Represents shares held by The Peterson Family Trust, a trust owned 100% by Mr. Peterson and his spouse.
F3: Represents shares held by Reporting Person's dependent child.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 02, 2025 Filed Jul 8, 2025 21:15 UTC | DataMeds AI, Inc. WGRX · Entity 8434 | GrantCommon Stock | 200,000 | $0.90 | $180,000.00 |
DisclosureSEC source: 0001641172-25-018239 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · shares: The shares shall fully vest solely on the basis of the passage of time, with 66,000 shares vesting immediately, 67,000 shares vesting on July 2, 2026, and 67,000 shares vesting on July 2, 2027. Read SEC document |
| October 23, 2023 Filed Oct 30, 2023 20:05 UTC | Trio Petroleum Corp TPET · Entity 8017 | GrantCommon Stock | 1,000,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-038667 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,185,000 F1 · kind: Mr. Peterson was awarded 1,000,000 shares of restricted stock (the "Stock Grant"), pursuant to the Issuer's 2022 Equity Incentive Plan (the "2022 Plan"), under the terms of an employment agreement entered into between the Issuer and Mr. Peterson, who became the Issuer's Chief Executive Officer, effective as of October 23, 2023. The Stock Grant has a vesting schedule in which the first 250,000 shares of restricted stock will vest on April 23, 2024, and the remainder shall vest in equal tranches of 250,000 shares each on October 23, 2024, April 23, 2025 and October 23, 2025, subject to Mr. Peterson's remaining in Continuous Service (as such term is defined under the 2022 Plan) with the Company as of each of those dates. F2 · price: The shares of restricted stock were awarded as a bonus under Mr. Peterson's employment agreement in connection with his services as the Chief Executive Officer of the Issuer. Read SEC document |
| September 01, 2023 Filed Sep 6, 2023 20:14 UTC | Trio Petroleum Corp TPET · Entity 8017 | GrantCommon Stock | 125,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-031821 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 F1 · kind: Mr. Peterson was awarded 125,000 shares of restricted stock, pursuant to the Issuer's 2022 Equity Incentive Plan. All of the shares of restricted stock vest on February 29, 2024, subject to Mr. Peterson continuing to be a director to the Company on such date. F2 · price: The shares of restricted stock were awarded as a bonus in connection with Mr. Peterson's services as an independent director of the Issuer. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:55 UTC | Ocean Biomedical, Inc. OCEA · Entity 8695 | OtherPrivate Placement Warrant · Derivative | 200,000 | Not disclosed Strike: $11.50 | Not disclosed |
DisclosureSEC source: 0001493152-23-006621 · ownership.xml · derivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2028-02-14 F5 · security: Simultaneously with the closing of the AHAC's initial public offering on September 17, 2021, the Sponsor purchased 5,411,000 warrants (the "Private Placement Warrants") from AHAC in a private placement at a price of $1.00 per warrant, pursuant to the terms of the Private Placement Warrants Purchase Agreement between AHAC and the Sponsor dated September 14, 2021 (the "Private Placement Agreement"). Upon the Reclassification that was effected in connection with the Closing of the Business Combination, each share of Class A Common Stock underlying the Private Placement Warrants was reclassified into a share of the Issuer's Common Stock. F6 · derivative.exercise_price: According to the original terms of the Private Placement Agreement, each Private Placement Warrant was exercisable to purchase one share of the Issuer's Class A Common Stock at an exercise price of $11.50 per share. The terms of the Private Placement Warrant were set forth in the Warrant Agreement, dated September 14, 2021, between AHAC and Continental Stock Transfer & Trust Company, LLC (the "Warrant Agreement"). The Private Placement Warrants become exercisable 30 days after the Closing of the Business Combination. F7 · date: On February 28, 2023, in accordance with the Instruction Letter, the Sponsor instructed its transfer agent to distribute these Private Placement Warrants to the Reporting Person. F7 · kind: On February 28, 2023, in accordance with the Instruction Letter, the Sponsor instructed its transfer agent to distribute these Private Placement Warrants to the Reporting Person. F5 · price: Simultaneously with the closing of the AHAC's initial public offering on September 17, 2021, the Sponsor purchased 5,411,000 warrants (the "Private Placement Warrants") from AHAC in a private placement at a price of $1.00 per warrant, pursuant to the terms of the Private Placement Warrants Purchase Agreement between AHAC and the Sponsor dated September 14, 2021 (the "Private Placement Agreement"). Upon the Reclassification that was effected in connection with the Closing of the Business Combination, each share of Class A Common Stock underlying the Private Placement Warrants was reclassified into a share of the Issuer's Common Stock. F7 · price: On February 28, 2023, in accordance with the Instruction Letter, the Sponsor instructed its transfer agent to distribute these Private Placement Warrants to the Reporting Person. F6 · derivative.exercise_date: According to the original terms of the Private Placement Agreement, each Private Placement Warrant was exercisable to purchase one share of the Issuer's Class A Common Stock at an exercise price of $11.50 per share. The terms of the Private Placement Warrant were set forth in the Warrant Agreement, dated September 14, 2021, between AHAC and Continental Stock Transfer & Trust Company, LLC (the "Warrant Agreement"). The Private Placement Warrants become exercisable 30 days after the Closing of the Business Combination. F8 · derivative.expiration_date: The Private Placement Warrants expire on the earlier to occur of (i) February 14, 2028, the date that is five years after the Closing of the Business Combination, (ii) at 5:00 p.m., New York City time on the Redemption Date (as defined in the Warrant Agreement), and (iii) the liquidation of the Trust Account (as defined in the Warrant Agreement). Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 21:55 UTC | Ocean Biomedical, Inc. OCEA · Entity 8695 | OtherCommon Stock, par value $0.0001 | 80,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001493152-23-006621 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 F1 · security: In connection with the closing on February 14, 2023 (the "Closing") of the business combination (the "Business Combination") between Aesther Healthcare Acquisition Corp. ("AHAC") and Ocean Biomedical Holdings, Inc., formerly known as Ocean Biomedical, Inc. ("Legacy Ocean"), pursuant to that certain Agreement and Plan of Merger, dated August 31, 2022 and amended on December 5, 2022, between AHAC, Aesther Healthcare Sponsor, LLC (the "Sponsor"), AHAC Merger Sub, Inc. ("Merger Sub"), Legacy Ocean, and Dr. Chirinjeev Kathuria, AHAC changed its name to Ocean Biomedical, Inc. (such post-Business Combination entity, the "Issuer"). F2 · security: Pursuant to the Issuer's Third Amended and Restated Certificate of Incorporation filed in connection with the Closing of the Business Combination, the Issuer completed a reclassification exempt under Rule 16b-7 (the "Reclassification"). In accordance with the Reclassification, each share of the Issuer's Class A Common Stock, par value $0.0001 per share (the "Class A Common Stock"), was reclassified on a one-for-one basis into a share of the Issuer's common stock, par value $0.0001 (the "Common Stock"). F3 · security: These shares were originally among the 2,625,000 shares of AHAC's Class B Common Stock, par value $0.0001 per share (the "Class B Founder Shares"), that the Sponsor owned prior to the Business Combination. In connection with the Closing of the Business Combination, the Class B Founder Shares automatically converted into shares of the Issuer's Class A Common Stock on a one-for-one basis, and the Class A Common Stock was then reclassified on a one-for-one basis into Common Stock in accordance with the Reclassification. F4 · kind: In accordance with an instruction letter to the Sponsor's transfer agent (the "Instruction Letter"), the Sponsor instructed the transfer agent to transfer 2,625,000 shares of Common Stock to certain of the Sponsor's members for no consideration (such transaction, the "Transfer"). As part of the Transfer, the Reporting Person acquired 80,000 shares of Common Stock from the Sponsor. F4 · shares: In accordance with an instruction letter to the Sponsor's transfer agent (the "Instruction Letter"), the Sponsor instructed the transfer agent to transfer 2,625,000 shares of Common Stock to certain of the Sponsor's members for no consideration (such transaction, the "Transfer"). As part of the Transfer, the Reporting Person acquired 80,000 shares of Common Stock from the Sponsor. F3 · price: These shares were originally among the 2,625,000 shares of AHAC's Class B Common Stock, par value $0.0001 per share (the "Class B Founder Shares"), that the Sponsor owned prior to the Business Combination. In connection with the Closing of the Business Combination, the Class B Founder Shares automatically converted into shares of the Issuer's Class A Common Stock on a one-for-one basis, and the Class A Common Stock was then reclassified on a one-for-one basis into Common Stock in accordance with the Reclassification. F4 · price: In accordance with an instruction letter to the Sponsor's transfer agent (the "Instruction Letter"), the Sponsor instructed the transfer agent to transfer 2,625,000 shares of Common Stock to certain of the Sponsor's members for no consideration (such transaction, the "Transfer"). As part of the Transfer, the Reporting Person acquired 80,000 shares of Common Stock from the Sponsor. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 20:24 UTC | Ocean Biomedical, Inc. OCEA · Entity 8695 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $10.00 | $0.00 |
DisclosureSEC source: 0001493152-23-005543 · ownership.xml · derivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: Represents a right to purchase 75,000 shares of the common stock, par value $0.0001 per share (collectively, the "Option Shares"), of Ocean Biomedical, Inc. (the "Issuer") upon the exercise of a ten-year option granted to the Reporting Person as a non-employee director of the Issuer on February 15, 2023 under the Issuer's 2022 Stock Option and Incentive Plan. This option becomes exercisable in 36 monthly installments beginning on March 15, 2023, with 2,083 Option Shares becoming exercisable on each of the first 35 installments and the remaining 2,095 Option Shares becoming exercisable on the final installment, subject to the Reporting Person remaining in service as a member of the Issuer's board of directors on each installment date. This option is exercisable at an exercise price per Option Share equal to the greater of (i) $10, or (ii) the closing trading price of the Issuer's common stock on February 15, 2023, which was $6.06. Read SEC document |
| January 16, 2023 Filed Jan 20, 2023 21:15 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantStock Option · Derivative | 135,802 | $0.00 Strike: $0.41 | $0.00 |
DisclosureSEC source: 0001493152-23-002029 · ownership.xml · derivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,802 Underlying: Common Stock · 135,802 shares Expires 2033-01-16 F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer and Chairperson of the Audit Committee. Issued under the Issuer's Amended and Restated 2019 Equity Incentive Plan. F3 · derivative.exercise_date: The options vest at the rate of 1/2 of such options per year, on January 4, 2024 and 2025, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3. Read SEC document |
| January 16, 2023 Filed Jan 20, 2023 21:15 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-23-002029 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,940 F1 · kind: Represents restricted stock shares subject to time-based vesting, which vest at the rate of 1/8th of such shares per quarter (on the first day of each calendar quarter), with the first vesting beginning on April 1, 2023, subject to the recipient's continued service to the Issuer. Exempt pursuant to Rule 16b-3. F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors of the Issuer and Chairperson of the Audit Committee. Issued under the Issuer's Amended and Restated 2019 Equity Incentive Plan. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 20:35 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | SaleCommon stock | 900 | $4.45 | $4,005.00 |
DisclosureSEC source: 0001493152-21-015010 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,387 F1 · kind: The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the April 2021 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3. Read SEC document |
| May 27, 2021 Filed Jun 2, 2021 20:45 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | Disposition to issuerCommon stock | 8,041 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-013437 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Former Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,287 F1 · kind: The shares were forfeited back to the Issuer as the reporting person's services to the Issuer ended on May 27, 2021, due to the vesting conditions pertaining to the award not having been achieved. Exempt under Rule 16b-3(e). Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:35 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 10,721 | $5.13 | $54,998.73 |
DisclosureSEC source: 0001493152-21-009257 · ownership.xml · nonDerivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,008 F3 · shares: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's Amended and Restated 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on July 1 and October 1, 2021 and January 1 and April 1, 2022, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F4 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors. Read SEC document |
| April 19, 2021 Filed Apr 20, 2021 20:35 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | SaleCommon stock | 900 | $4.68 | $4,212.00 |
DisclosureSEC source: 0001493152-21-009257 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,287 F1 · kind: The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the April 2021 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3. F2 · price: This transaction was executed in multiple trades at prices ranging from $4.63 to $4.77, with the price reported above reflecting the weighted average sales price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was affected. Read SEC document |
| December 14, 2020 Filed Dec 16, 2020 02:23 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | SaleCommon stock | 1,800 | $5.26 | $9,460.08 |
DisclosureSEC source: 0001493152-20-023703 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,187 F1 · shares: The shares were sold pursuant to a 10b5-1 trading plan previously adopted by the Reporting Person, to satisfy the Reporting Person's tax liability in connection with the December 2020 vesting of certain restricted stock shares which were granted under the Company's 2019 Equity Incentive Plan, which award was exempt from Section 16(b) pursuant to Rule 16b-3. F2 · price: Represents the weighted sales price for all sales made on December 14, 2020, which were made in a range of between $5.22 and $5.30 per share. The Reporting Person will provide to the Commission, the Issuer or any stockholder, upon request, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 00:00 UTC | Scienture Holdings, Inc. MEDS · Entity 7802 | GrantCommon stock | 8,987 | $6.12 | $55,000.44 |
DisclosureSEC source: 0001493152-20-006499 · ownership.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,987 F1 · shares: Shares of Restricted Common Stock were issued to the Reporting Person pursuant to the Issuer's 2019 Equity Incentive Plan and are subject to forfeiture. The shares vest at the rate of 1/4 of the shares on July 1 and October 1, 2020 and January 1 and April 1, 2021, subject to the Reporting Person's continued service to the Company on such vesting dates, and subject to the terms and conditions of a Restricted Shares Grant Agreement entered into by and between the Issuer and the Reporting Person. Exempt under Rule 16b-3(d). F2 · price: Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a member of the Board of Directors. Read SEC document |
| May 13, 2019 Filed May 14, 2019 19:43 UTC | Scienture Holdings, Inc. TRXD · Entity 7802 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0001078782-19-000428 · primary_doc.xml · derivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,923 Underlying: Common Stock · 50,000 shares Expires 2019-05-13 F1 · derivative.exercise_date: Option vests and becomes exercisable quarterly over four years. Read SEC document |
| June 28, 2018 Filed Jun 29, 2018 20:17 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 119,000 | $2.96 | $351,787.80 |
DisclosureSEC source: 0001654954-18-007178 · section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Contractor 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 442,081 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the June 28, 2018 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). Read SEC document |
| April 26, 2018 Filed Apr 30, 2018 21:43 UTC | Scienture Holdings, Inc. TRXD · Entity 7802 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001078782-18-000490 · primary_doc.xml · derivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,423 Underlying: Common Stock · 50,000 shares Expires 2028-04-01 F1 · derivative.exercise_date: Option vests and becomes exercisable quarterly over four years. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 21:32 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 24,750 | $0.31 | $7,637.85 |
DisclosureSEC source: 0001654954-17-011944 · section16.xml · nonDerivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 561,081 F2 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the December 28, 2017 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). F3 · balance_after: Reporting Person's holdings include: 4,500; 18,875; 8,700; 8,500; 7,725; 3,021; 99,000 and 410,000 shares all issued pursuant to restricted stock grants; 745 issued pursuant to debt conversion and 15 pursuant to a 2008 Blast Stock Grant. Read SEC document |
| December 28, 2017 Filed Dec 29, 2017 21:32 UTC | PEDEVCO CORP PED · Entity 6361 | GrantCommon Stock | 410,000 | $0.31 | $126,608.00 |
DisclosureSEC source: 0001654954-17-011944 · section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 585,831 F1 · shares: Common stock of Issuer granted to Reporting Person pursuant to Issuer's 2012 Equity Incentive Plan and subject to forfeiture as follows: (i) 50% of the shares on the six (6) month anniversary of the Grant Date; (ii) 30% on the twelve (12) month anniversary of the Grant Date and (iii) 20% on the eighteen (18) month anniversary of the Grant Date, in each case subject to the Recipient being an employee of, or consultant to the Company on such vesting date, and subject to the terms and conditions of a Restricted Stock Agreement. Read SEC document |
| October 09, 2017 Filed Oct 11, 2017 21:05 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 1,500 | $0.39 | $586.20 |
DisclosureSEC source: 0001654954-17-009330 · section16.xml · nonDerivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,831 F2 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person with respect to the sale of shares which vested on October 8, 2017 which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). F3 · balance_after: Reporting Person's holdings include: 4,500; 18,875; 8,700; 8,500; 7725; 3,021 and 123,750 shares all issued pursuant to restricted stock grants; 745 issued pursuant to debt conversion and 15 pursuant to a 2008 Blast stock grant. Read SEC document |
| September 07, 2017 Filed Oct 11, 2017 21:05 UTC | PEDEVCO CORP PED · Entity 6361 | GiftCommon Stock | 20,000 | $0.25 | $5,000.00 |
DisclosureSEC source: 0001654954-17-009330 · section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,331 F1 · shares: Common stock shares were transferred pursuant to a gift in a private transaction. Read SEC document |
| July 10, 2017 Filed Jul 10, 2017 21:17 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 1,748 | $0.61 | $1,071.70 |
DisclosureSEC source: 0001654954-17-006277 · section16.xml · nonDerivative · entry 3 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,331 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person with respect to the sale of shares which vested on July 1, 2017 and July 7, 2017 which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). F2 · balance_after: Reporting Person's holdings include: 4,500; 18,875; 8,700; 10,000; 7,725; 23,021 and 123,750 shares all issued pursuant to restricted stock grants; 745 issued pursuant to debt conversion and 15 pursuant to a 2008 Blast stock grant. Read SEC document |
| July 07, 2017 Filed Jul 10, 2017 21:17 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 300 | $0.61 | $181.80 |
DisclosureSEC source: 0001654954-17-006277 · section16.xml · nonDerivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,079 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person with respect to the sale of shares which vested on July 1, 2017 and July 7, 2017 which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). Read SEC document |
| July 07, 2017 Filed Jul 10, 2017 21:17 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 6,000 | $0.61 | $3,676.80 |
DisclosureSEC source: 0001654954-17-006277 · section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,379 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person with respect to the sale of shares which vested on July 1, 2017 and July 7, 2017 which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). Read SEC document |
| June 30, 2017 Filed Jun 30, 2017 21:04 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 8,250 | $0.60 | $4,964.03 |
DisclosureSEC source: 0001654954-17-006058 · section16.xml · nonDerivative · entry 4 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 205,379 F2 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person with respect to the sale of shares which vested on June 28, 2017 which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). F3 · balance_after: Reporting Person's holdings include: 4,500; 18,875; 10,675; 10,000; 7,725; 29,094 and 123,750 shares all issued pursuant to restricted stock grants; 745 issued pursuant to debt conversion and 15 pursuant to a 2008 Blast stock grant. Read SEC document |
| June 29, 2017 Filed Jun 30, 2017 21:04 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 16,500 | $0.63 | $10,390.05 |
DisclosureSEC source: 0001654954-17-006058 · section16.xml · nonDerivative · entry 3 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,629 F2 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person with respect to the sale of shares which vested on June 28, 2017 which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). Read SEC document |
| June 28, 2017 Filed Jun 30, 2017 21:04 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 16,500 | $0.63 | $10,390.05 |
DisclosureSEC source: 0001654954-17-006058 · section16.xml · nonDerivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,129 F2 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person with respect to the sale of shares which vested on June 28, 2017 which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). Read SEC document |
| April 12, 2017 Filed Jun 30, 2017 21:04 UTC | PEDEVCO CORP PED · Entity 6361 | GiftCommon Stock | 10,000 | $0.10 | $1,030.00 |
DisclosureSEC source: 0001654954-17-006058 · section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,629 F1 · shares: Common shares were transferred pursuant to a gift in a private transaction. Read SEC document |
| April 10, 2017 Filed Apr 11, 2017 20:19 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 1,500 | $1.11 | $1,672.20 |
DisclosureSEC source: 0001354488-17-000458 · issuerdirect_section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,629 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the April 8, 2017 vesting of shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). F4 · balance_after: Reporting Person's holdings include: 4,500; 19,875; 10,675; 10,000; 7,725; 38,094 and 165,000 shares all issued pursuant to restricted stock grants; 745 issued pursuant to debt conversion and 15 pursuant to a 2008 Blast stock grant. Read SEC document |
| April 07, 2017 Filed Feb 14, 2018 23:19 UTC | Scienture Holdings, Inc. TRXD · Entity 7802 | GrantStock Option · Derivative | 176,923 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001078782-18-000165 · primary_doc.xml · derivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 176,923 shares Expires 2027-04-01 F1 · derivative.exercise_date: 76,923 of the options vest after one year, the remaining Options vest quarterly over four years. Read SEC document |
| January 11, 2017 Filed Jan 11, 2017 23:41 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 58,250 | $0.10 | $5,999.75 |
DisclosureSEC source: 0001354488-17-000061 · issuerdirect_section16.xml · nonDerivative · entry 3 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,581,278 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the January 1, 2017 and January 7, 2017 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). F4 · balance_after: Reporting Person's holdings include: 45,000, 198,750, 106,750, 115,000, 77,245, 380,935 and 1,650,000 shares all issued pursuant to restricted stock grants; 7,449 issued pursuant to debt conversion and 149 issued pursuant to a 2008 Blast stock grant. Read SEC document |
| January 10, 2017 Filed Jan 11, 2017 23:41 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 40,000 | $0.10 | $4,080.00 |
DisclosureSEC source: 0001354488-17-000061 · issuerdirect_section16.xml · nonDerivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,639,528 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the January 1, 2017 and January 7, 2017 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). Read SEC document |
| January 09, 2017 Filed Jan 11, 2017 23:41 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 44,000 | $0.11 | $4,708.00 |
DisclosureSEC source: 0001354488-17-000061 · issuerdirect_section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,679,528 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the January 1, 2017 and January 7, 2017 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 22:19 UTC | PEDEVCO CORP PED · Entity 6361 | GrantCommon Stock | 1,650,000 | $0.11 | $181,500.00 |
DisclosureSEC source: 0001354488-16-008750 · issuerdirect_section16.xml · nonDerivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,723,528 F2 · shares: Common stock of Issuer granted to Reporting Person and subject to forfeiture as follows: (i) 50% of the shares on the six (6) month anniversary of the Grant Date; (ii) 30% on the twelve (12) month anniversary of the Grant Date; and (iii) 20% on the eighteen (18) month anniversary of the Grant Date, in each case subject to the Recipient being an employee of, or consultant to, the Company on such vesting date, and subject to the terms and conditions of a Restricted Stock Agreement. F3 · balance_after: Reporting Person's holdings include: 45,000, 198,750, 126,500, 115,000, 109,745, 470,935 and 1,650,000 shares all issued pursuant to restricted stock grants; 7,449 issued pursuant to debt conversion and 149 issued pursuant to a 2008 Blast Stock Grant. Read SEC document |
| December 28, 2016 Filed Dec 30, 2016 22:18 UTC | PEDEVCO CORP PED · Entity 6361 | GrantCommon Stock | 1,650,000 | $0.11 | $181,500.00 |
DisclosureSEC source: 0001354488-16-008748 · issuerdirect_section16.xml · nonDerivative · entry 2 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,723,528 F2 · shares: Common stock of Issuer granted to Reporting Person and subject to forfeiture as follows: (i) 50% of the shares on the six (6) month anniversary of the Grant Date; (ii) 30% on the twelve (12) month anniversary of the Grant Date; and (iii) 20% on the eighteen (18) month anniversary of the Grant Date, in each case subject to the Recipient being an employee of, or consultant to, the Company on such vesting date, and subject to the terms and conditions of a Restricted Stock Agreement. F3 · balance_after: Reporting Person's holdings include: 45,000, 198,750, 126,500, 115,000, 109,745, 470,935 and 1,650,000 shares all issued pursuant to restricted stock grants; 7,449 issued pursuant to debt conversion and 149 issued pursuant to a 2008 Blast Stock Grant. Read SEC document |
| December 12, 2016 Filed Dec 30, 2016 22:19 UTC | PEDEVCO CORP PED · Entity 6361 | GiftCommon Stock | 50,000 | $0.17 | $8,500.00 |
DisclosureSEC source: 0001354488-16-008750 · issuerdirect_section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,073,528 F1 · shares: Common shares were transferred pursuant to a gift in a private transaction. Read SEC document |
| December 12, 2016 Filed Dec 30, 2016 22:18 UTC | PEDEVCO CORP PED · Entity 6361 | GiftCommon Stock | 50,000 | $0.17 | $8,500.00 |
DisclosureSEC source: 0001354488-16-008748 · issuerdirect_section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,073,528 F1 · shares: Common shares were transferred pursuant to a gift in a private transaction. Read SEC document |
| October 10, 2016 Filed Oct 12, 2016 20:30 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 15,000 | $0.18 | $2,682.00 |
DisclosureSEC source: 0001354488-16-008381 · issuerdirect_section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,123,528 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the October 8, 2016 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). F2 · balance_after: Reporting Person's holdings include: 45,000; 198,750; 126,500; 165,000 109,745 and 470,935 shares issued pursuant to restricted stock grants; 7,449 issued pursuant to debt conversion and 149 issued pursuant to a 2008 Blast stock grant. Read SEC document |
| September 07, 2016 Filed Sep 9, 2016 20:15 UTC | PEDEVCO CORP PED · Entity 6361 | SaleCommon Stock | 32,500 | $0.17 | $5,616.00 |
DisclosureSEC source: 0001354488-16-008275 · issuerdirect_section16.xml · nonDerivative · entry 1 PETERSON MICHAEL L · CIK 0001293970 · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,138,528 F1 · shares: Shares were sold pursuant to a 10b5-1 trading plan previously adopted by Reporting Person to satisfy Reporting Person's tax liability in connection with the September 7, 2016 vesting of certain shares of restricted stock which were granted under the Company's 2012 Equity Incentive Plan, which grants were exempt from Section 16(b) pursuant to Rule 16b-13(d). F2 · balance_after: Reporting Person's holdings include: 45,000; 198,750; 126,500; 180,000; 109,745 and 470,935 shares issued pursuant to restricted stock grants; 7,449 issued pursuant to debt conversion and 149 issued pursuant to a 2008 Blast stock grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.